Literature DB >> 10070900

Oestrogen receptor-alpha variant mRNA expression in primary human breast tumours and matched lymph node metastases.

E Leygue1, R E Hall, H Dotzlaw, P H Watson, L C Murphy.   

Abstract

We have shown previously that the relative expression of a truncated oestrogen receptor-alpha variant mRNA (ER clone 4) is significantly increased in axillary node-positive primary breast tumours compared with node-negative tumours. In this study, we have examined the relative expression of clone 4-truncated, exon 5-deleted and exon 7-deleted oestrogen receptor-alpha variant mRNAs in 15 primary breast tumour samples and in synchronous axillary lymph node metastases. Overall, there were no significant differences between the primary tumours and the matched metastases in the relative expression of these three specific variant mRNAs. Furthermore, the pattern of all deleted oestrogen receptor-alpha variant mRNAs appeared conserved between any primary and its matched secondary tumour.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10070900      PMCID: PMC2362647          DOI: 10.1038/sj.bjc.6690156

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

1.  Detection of wild type and exon 5-deleted splice variant oestrogen receptor (ER) mRNA in ER-positive and -negative breast cancer cell lines by reverse transcription/polymerase chain reaction.

Authors:  A A Daffada; S R Johnston; J Nicholls; M Dowsett
Journal:  J Mol Endocrinol       Date:  1994-12       Impact factor: 5.098

2.  Characterization of estrogen receptor variant mRNAs from human breast cancers.

Authors:  H Dotzlaw; M Alkhalaf; L C Murphy
Journal:  Mol Endocrinol       Date:  1992-05

3.  The relationship between estrogen receptors in primary and secondary breast carcinomas and in sequential primary breast carcinomas.

Authors:  R Hähnel; E Twaddle
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

4.  Variant estrogen receptor mRNA species detected in human breast cancer biopsy samples.

Authors:  L C Murphy; H Dotzlaw
Journal:  Mol Endocrinol       Date:  1989-04

5.  Multistep progression from an oestrogen-dependent growth towards an autonomous growth in breast carcinogenesis.

Authors:  F C Schmitt
Journal:  Eur J Cancer       Date:  1995-11       Impact factor: 9.162

6.  Estrogen receptor expression of benign breast epithelium and its association with breast cancer.

Authors:  S A Khan; M A Rogers; J A Obando; A Tamsen
Journal:  Cancer Res       Date:  1994-02-15       Impact factor: 12.701

7.  Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.

Authors:  A A Daffada; S R Johnston; I E Smith; S Detre; N King; M Dowsett
Journal:  Cancer Res       Date:  1995-01-15       Impact factor: 12.701

8.  Epidermal growth factor gene expression in human breast cancer biopsy samples: relationship to estrogen and progesterone receptor gene expression.

Authors:  H Dotzlaw; T Miller; J Karvelas; L C Murphy
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

9.  Identification of a variant estrogen receptor lacking exon 4 and its coexpression with wild-type estrogen receptor in ovarian carcinomas.

Authors:  W Park; J J Choi; E S Hwang; J H Lee
Journal:  Clin Cancer Res       Date:  1996-12       Impact factor: 12.531

Review 10.  Oestrogen receptor: a stable phenotype in breast cancer.

Authors:  J F Robertson
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

View more
  2 in total

Review 1.  The role of estrogen receptors in breast cancer metastasis.

Authors:  S A Fuqua
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

2.  Altered expression of estrogen receptor-alpha variant messenger RNAs between adjacent normal breast and breast tumor tissues.

Authors:  E Leygue; H Dotzlaw; P H Watson; L C Murphy
Journal:  Breast Cancer Res       Date:  2000       Impact factor: 6.466

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.